Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neupath Health Inc. ( (TSE:NPTH) ) has shared an update.
NeuPath Health Inc. has announced a planned leadership transition that will see current President Stephen Lemieux, a seasoned healthcare finance and operations executive, take over as chief executive officer on April 1, 2026, while incumbent CEO Joseph Walewicz will remain on the board and act as a consultant to ensure strategic continuity; the company has also elevated veteran technology executive Sandee Dela Cruz to the newly created role of chief information officer to drive IT strategy in support of its growth plans. Alongside these governance changes, NeuPath pre-announced a strong set of preliminary 2025 results, projecting revenue between $86 million and $88 million and adjusted EBITDA of $5.6 million to $6.0 million, marking a substantial year-on-year improvement that underpins confidence in its growth strategy and signals to investors and other stakeholders that its operational and digital transformation initiatives are translating into stronger financial performance ahead of the full results release in March 2026.
The most recent analyst rating on (TSE:NPTH) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Neupath Health Inc. stock, see the TSE:NPTH Stock Forecast page.
More about Neupath Health Inc.
NeuPath Health Inc., listed on the TSX Venture Exchange, operates in the healthcare sector with a focus on pain management and related clinical services, expanding its footprint across Canada through both organic growth and acquisitions such as the 2021 purchase of HealthPointe, which strengthened its presence in Western Canada.
Average Trading Volume: 185,132
Technical Sentiment Signal: Buy
Current Market Cap: C$30.47M
Find detailed analytics on NPTH stock on TipRanks’ Stock Analysis page.